Farallon Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Farallon Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,670	Closed	-$341K	–	127
2020 Q1	$341K	Sell	1,670 -34,815	-95%	-$11.1M	﹤0.01%	101
2019 Q4	$16.3M	Sell	36,485 -1,015	-3%	-$360K	0.11%	90
2019 Q3	$11.5M	Buy	37,500 +4,167	+13%	+$1.35M	0.09%	84
2019 Q2	$10.6M	Buy	+33,333	New	+$11.5M	0.07%	84
2015 Q2	–	Sell	-89	Closed	-$758K	–	99
2015 Q1	$758K	Sell	89 -355	-80%	-$3.1M	0.01%	91
2014 Q4	$3.91M	Hold	444	–	–	0.05%	78
2014 Q3	$2.09M	Hold	444	–	–	0.03%	77
2014 Q2	$3.2M	Sell	444 -160	-26%	-$801K	0.05%	83
2014 Q1	$3.24M	Buy	+604	New	+$2.85M	0.06%	69

Other funds holding EIGR

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Farallon Capital Management's EIGR Position: Q2 2020 in Review

Farallon Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 1,670 shares — an estimated $341K sold.

Farallon Capital Management first reported a position in EIGR in Q1 2014 and held it in 9 quarters. The position peaked at $16.3M in Q4 2019. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

Farallon Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Farallon Capital Management sold 1,670 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $341K.
Farallon Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 9 quarters.
Farallon Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $16.3M in Q4 2019.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.